Life Science Investing Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® Over Five Years
Life Science Investing CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering
Life Science Investing Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines
Life Science Investing CSL Behring Signs Letter of Intent with pan-Canadian Pharmaceutical Alliance for Public Reimbursement of HEMGENIX® , the First Gene Therapy for Hemophilia B
Life Science Investing CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
Nextech3D.ai Closes Krafty Labs Acquisition Expanding into a Comprehensive End-to-End AI-Powered Live Events and Experiential Engagement Platform
LaFleur Minerals Closes LIFE, Flow Thru and Final Hard Dollar Offering for $900,000 to Complete Total of $7,800,421 Funding to Restart Beacon Gold Mill Production Operations in Abitibi Greenstone Belt
